Summary
60.56 -0.15(-0.25%)10/04/2024
Catalent Inc. (CTLT)
Catalent Inc. (CTLT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.25 | 0.38 | -0.23 | 6.71 | 6.35 | 40.22 | 23.34 | 202.95 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 60.56 | |
| Open | 60.75 | |
| High | 60.75 | |
| Low | 60.50 | |
| Volume | 655,710 | |
| Change | -0.15 | |
| Change % | -0.25 | |
| Avg Volume (20 Days) | 1,141,616 | |
| Volume/Avg Volume (20 Days) Ratio | 0.57 | |
| 52 Week Range | 31.80 - 61.20 | |
| Price vs 52 Week High | -1.05% | |
| Price vs 52 Week Low | 90.44% | |
| Range | -0.31 | |
| Gap Up/Down | 0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 10,940 | |
| EBIDTA | 355,000,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.0565 | |
| WallStreet Target Price | 56.70 | |
| Book Value | 19.9600 | |
| Earnings Per Share | -6.4800 | |
| EPS Estimate Current Quarter | 0.2100 | |
| EPS Estimate Next Quarter | 0.6400 | |
| EPS Estimate Current Year | 0.3700 | |
| EPS Estimate Next Year | 1.2500 | |
| Diluted EPS (TTM) | -6.4800 | |
| Revenues | ||
| Profit Marging | -0.2844 | |
| Operating Marging (TTM) | 0.0056 | |
| Return on asset (TTM) | -0.0071 | |
| Return on equity (TTM) | -0.2829 | |
| Revenue TTM | 4,135,000,064 | |
| Revenue per share TTM | 22.7510 | |
| Quarterly Revenue Growth (YOY) | 0.0360 | |
| Quarterly Earnings Growth (YOY) | -0.1540 | |
| Gross Profit (TTM) | 1,040,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 37.8788 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.7598 | |
| Revenue Enterprise Value | 3.6507 | |
| EBITDA Enterprise Value | -19.8416 | |
| Shares | ||
| Shares Outstanding | 180,980,000 | |
| Shares Float | 179,960,932 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 0.50 | |
| Institutions (%) | 105.26 | |
10/03 15:01 EST - zacks.com
More Interest Rate Cuts Ahead: 5 Growth Stocks to Benefit
These fives stocks have strong growth potential for the rest of 2024. These are: APP, DUOL, PARAA, TWLO, CTLT.
More Interest Rate Cuts Ahead: 5 Growth Stocks to Benefit
These fives stocks have strong growth potential for the rest of 2024. These are: APP, DUOL, PARAA, TWLO, CTLT.
10/03 12:46 EST - zacks.com
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
09/12 13:00 EST - zacks.com
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
08/30 17:33 EST - reuters.com
Catalent delays filing of annual report
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent delays filing of annual report
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
08/30 12:51 EST - zacks.com
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
08/29 09:46 EST - zacks.com
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
08/29 08:07 EST - reuters.com
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
08/06 12:41 EST - zacks.com
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
07/17 12:46 EST - zacks.com
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
07/16 13:31 EST - zacks.com
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
07/16 12:46 EST - zacks.com
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?
07/16 02:00 EST - businesswire.com
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The expansion increases the site's footprint by 32,000 square feet (3,000 square meters.
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The expansion increases the site's footprint by 32,000 square feet (3,000 square meters.
07/15 12:46 EST - zacks.com
UTHR or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
UTHR or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
06/21 13:52 EST - benzinga.com
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
06/07 12:36 EST - zacks.com
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
05/29 09:21 EST - reuters.com
Catalent stockholders approve deal with Novo Holdings
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
Catalent stockholders approve deal with Novo Holdings
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
05/29 09:07 EST - businesswire.com
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.
05/29 09:00 EST - businesswire.com
Surely Wines Appoints Brandon Joldersma as New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Officer, effective February 2024. Joldersma's appointment coincides with a new fundraising round led by Pure Ventures, with additional investors joining Surely's mission to elevate the alcohol-free and low-alcohol beverage market while expanding its offerings within this burgeoning industry. “I'm hon.
Surely Wines Appoints Brandon Joldersma as New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Officer, effective February 2024. Joldersma's appointment coincides with a new fundraising round led by Pure Ventures, with additional investors joining Surely's mission to elevate the alcohol-free and low-alcohol beverage market while expanding its offerings within this burgeoning industry. “I'm hon.
05/13 12:21 EST - zacks.com
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
05/09 14:35 EST - zacks.com
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.